Faeth Therapeutics, Inc 10-Q for FY2026 Q3
Faeth Therapeutics, Inc. (FTH)
10-Q
2026-11-03
For: 2026-09-30
View Original
Added on
November 03, 2026
About this 10-Q
Faeth Therapeutics, Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Faeth Therapeutics, Inc. reported a $206.6 million net loss for the nine months ended September 30, 2026, driven largely by $133.0 million of acquired IPR&D expense, while $174.8 million in cash and marketable securities supports PIKTOR trials through topline data. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $20.4M
- compared with a net loss of $4.57M a year earlier
- Diluted EPS
- -$0.79
- compared with -$3.62 a year earlier